Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers

A study in mice and in human cancer cell lines, combining the diet with vitamin C, plus an analysis of existing patient records. No patient was given the diet.

Nat Commun, 2020. Di Tano M, et al.

Funding and competing interests (from the paper, shortened): V.D.L. has equity interest in L-Nutra. A.N. and I.C. are inventors of three patents that were licenced to L-Nutra. All the other authors declare no competing interest.

Read the full study

Opens the journal or PubMed page in a new tab. Some journals require a subscription.

Study type
Animal study (mice), with human cancer cell lines studied in vitro and a database analysis
Journal
Nat Commun
Published
2020
Authors
Di Tano M, et al.
DOI
10.1038/s41467-020-16243-3
PubMed ID
32393788

Summary

Researchers combined a Fasting Mimicking Diet (FMD) with vitamin C in mice and in cancer cell lines, with and without chemotherapy, focusing on KRAS-mutant tumours. They measured the stress-inducible protein heme-oxygenase-1, ferritin, reactive iron, reactive oxygen species and cell death. They also analysed The Cancer Genome Atlas database to relate intratumour ferritin expression to survival in patients with KRAS-mutated colorectal cancer.

The authors reported that the anticancer activity of vitamin C was limited by up-regulation of heme-oxygenase-1, and that the diet selectively reversed the vitamin C-induced up-regulation of heme-oxygenase-1 and ferritin in KRAS-mutant cancer cells, increasing reactive iron, reactive oxygen species and cell death, with a further increase when chemotherapy was added. In the database analysis they reported that patients with KRAS-mutated colorectal cancer and low intratumour ferritin expression had longer three-year and five-year overall survival. They describe the combination as a promising low toxicity intervention to be tested in randomized clinical trials.

These findings come from mice, from cancer cell lines and from a database analysis, not from patients given the diet, and this is not a study of Prolon. The human element is an association between a gene expression level and survival in existing records, with no dietary intervention involved. The laboratory effects depended on vitamin C and in part on chemotherapy, so the diet is not assessed on its own. The authors state that randomized clinical trials have yet to be done.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.